TD Cowen analyst Phil Nadeau reiterated a Buy rating on Syros Pharmaceuticals (NASDAQ: SYRS).The analyst commented, "SYRS hosted a webcast ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE